Commentary
Video
Sundar Jagannath, MD, MBBS, discusses how linvoseltamab’s streamlined step-up dosing and REMS program support broader use in community settings and improved tolerability for older patients.
In an interview with Pharmacy Times®, Sundar Jagannath, MD, MBBS, professor of medicine—hematology and oncology at Mount Sinai Health System, outlines the practical benefits of FDA-approved linvoseltamab's (Lynozyfic; Regeneron) stepped-up dosing strategy, which is designed to minimize cytokine release syndrome (CRS) while enhancing tolerability—particularly in older or frail patients.
Jagannath also discusses the evolving role of pharmacists under the FDA's Risk Evaluation and Management Strategies (REMS) program, emphasizing the need for team-wide education as linvoseltamab decentralizes from academic to community settings. Unlike CAR T-cell therapy, linvoseltamab can be administered without specialized infrastructure, making it a scalable, pharmacist-enabled solution for relapsed multiple myeloma.
Pharmacy Times: What can be expected throughout the administration of linvoseltamab, specifically regarding the step-up dosing strategy?
Sundar Jagannath, MD, MBBS: This is currently the easiest step-up dosing for a BCMA bispecific. It's given once weekly for the first 2 weeks, starting with 5 mg (about 1/40 of the full dose), followed by 25 mg (about 1/8), and then the full 200 mg. Each dose includes 24 hours of observation. If tocilizumab is given during the second step-up dose, it stays in the system for 7–10 days or more. So by the time the full dose is administered, the patient may not experience any reaction at all. The strategy is especially good for elderly or frail patients. Today, we even see 90-year-olds coming in with family to explore options. The treatments have improved so much that these patients are able to tolerate options like daratumumab. If they relapse, they’re ideal candidates for something like linvoseltamab. In the past, we used to rely on transplants, but that has its age limits—65 in Europe and maybe up to 75 in the U.S., according to Medicare. But transplant utilization is not high. Bispecifics like linvoseltamab are more widely accessible and better tolerated, which is what we need.
Pharmacy Times: How might the step-up dosing strategy and the REMS program influence how pharmacists prepare, dispense, or educate providers and patients about linvoseltamab?
Jagannath: Pharmacists are deeply involved now. The REMS program requires hospitals to ensure that infusion nurses, clinicians, and pharmacists are familiar with the drug. While REMS requirements have been somewhat relaxed, education remains crucial. At Mount Sinai, we often receive referrals from across the tri-state area. Private oncologists will let us do the initial step-up dosing, then take over treatment. That means their teams also need to be educated. Compared to CAR T-cell therapy—which requires FACT accreditation and a cellular therapy infrastructure—bispecifics like linvoseltamab are much easier to implement in community settings. So I believe there will be greater uptake of bispecifics, thanks in part to their ease of use and the role of pharmacists in enabling that.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
